{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=19", "query": { "condition": "Metastatic Breast Carcinoma", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 2114, "total_pages": 212, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T06:43:57.684Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01366144", "title": "Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Carcinoma", "Carcinoma of Unknown Primary", "Endometrial Carcinoma", "Esophageal Carcinoma", "Liver Failure", "Lung Carcinoma", "Malignant Head and Neck Neoplasm", "Malignant Testicular Neoplasm", "Melanoma", "Metastatic Malignant Solid Neoplasm", "Ovarian Carcinoma", "Renal Failure", "Unresectable Malignant Neoplasm", "Urothelial Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2011-06-20", "completion_date": "2027-03-03", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-15T06:43:57.684Z", "location_count": 17, "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01366144" }, { "nct_id": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Metastatic Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "Zongertinib", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "zanidatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 768, "start_date": "2024-06-28", "completion_date": "2029-01-08", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-15T06:43:57.684Z", "location_count": 26, "location_summary": "Cerritos, California • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06324357" }, { "nct_id": "NCT02964507", "title": "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK525762", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 124, "start_date": "2019-09-26", "completion_date": "2021-07-19", "has_results": true, "last_update_posted_date": "2024-08-29", "last_synced_at": "2026-10-15T06:43:57.684Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02964507" }, { "nct_id": "NCT00951665", "title": "A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "pertuzumab [Perjeta]", "type": "DRUG" }, { "name": "trastuzumab emtansine [Kadcyla]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2009-08", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2016-06-24", "last_synced_at": "2026-10-15T06:43:57.684Z", "location_count": 5, "location_summary": "Stanford, California • Aurora, Colorado • Boston, Massachusetts + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00951665" }, { "nct_id": "NCT00243503", "title": "Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "SU011248/Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2006-02", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2011-07-22", "last_synced_at": "2026-10-15T06:43:57.684Z", "location_count": 16, "location_summary": "Montgomery, Alabama • Newark, Delaware • Wilmington, Delaware + 11 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00243503" }, { "nct_id": "NCT00875979", "title": "A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Trastuzumab emtansine [Kadcyla] 3.0 mg/kg", "type": "DRUG" }, { "name": "Trastuzumab emtansine [Kadcyla] 3.6 mg/kg", "type": "DRUG" }, { "name": "Pertuzumab 420 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2009-05", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2013-12-24", "last_synced_at": "2026-10-15T06:43:57.684Z", "location_count": 10, "location_summary": "Boca Raton, Florida • Deerfield Beach, Florida • Maywood, Illinois + 6 more", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00875979" }, { "nct_id": "NCT00216073", "title": "Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoosier Cancer Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2004-03", "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2011-05-02", "last_synced_at": "2026-10-15T06:43:57.684Z", "location_count": 11, "location_summary": "Galesburg, Illinois • Bloomington, Indiana • Elkhart, Indiana + 6 more", "locations": [ { "city": "Galesburg", "state": "Illinois" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Elkhart", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00216073" }, { "nct_id": "NCT00725946", "title": "Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer", "Breast Cancer Early Stage Breast Cancer (Stage 1-3)", "Breast Cancer Metastatic Breast Cancer" ], "interventions": [ { "name": "Iodine-124", "type": "DRUG" }, { "name": "PET/CT with Iodine-124", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 7, "start_date": "2008-02", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2017-10-11", "last_synced_at": "2026-10-15T06:43:57.684Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00725946" }, { "nct_id": "NCT00089973", "title": "Study Of Ispinesib In Subjects With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Ispinesib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2004-06-30", "completion_date": "2006-08-25", "has_results": true, "last_update_posted_date": "2018-02-26", "last_synced_at": "2026-10-15T06:43:57.684Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089973" }, { "nct_id": "NCT02981303", "title": "Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Melanoma", "Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Imprime PGG", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "HiberCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2017-02-22", "completion_date": "2020-12-31", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-10-15T06:43:57.684Z", "location_count": 10, "location_summary": "Avondale, Arizona • Santa Monica, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Avondale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Athens", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02981303" } ] }